← Back to Encyclopedia
📚 THE PAPER TRAIL
WE HAVE RECEIPTS.
Every recommendation should earn trust. Apex now grades peptide claims by evidence type — FDA label, human trial, animal model, in vitro mechanism, extrapolation, or real-world use — so beginners get simple guidance and advanced users can inspect the paper trail.
THE APEX DIFFERENCE
Most peptide apps are Instagram stacks in a spreadsheet.
Apex is being rebuilt around evidence grading.
The standard is a 4-layer review: regulatory labels → peer-reviewed human evidence → preclinical/mechanistic evidence → real-world protocol conventions. When evidence is strong, we say so. When evidence is indirect or extrapolated, we say that too.
The target state is simple: every dose and mechanism claim should show its evidence grade and source basis. Until a peptide has that ledger, it should be treated as research context — not medical instruction.
01 / BY THE NUMBERS

Our Research Standards

GRADE
EVIDENCE PER CLAIM
43
PEPTIDES CATALOGED
7
FDA-APPROVED CITED
AUDIT
CLAIM REVIEW QUEUE
02 / EVIDENCE GRADING

How To Read Confidence

Important: citation volume is not the same as clinical certainty. A peptide can have hundreds of papers on a related molecule or mechanism and still have limited direct human evidence for the exact compound, route, dose, and goal shown in the app.
A · Strong Human / Regulatory Evidence

FDA label, large randomized human trial, or multiple controlled human studies using the same compound and route.

B · Human Evidence With Limits

Small human trials, observational data, adjacent-route data, or clinical evidence for a closely related molecule.

C · Translational / Preclinical Evidence

Animal, cell, mechanistic, or biomarker research. Useful for hypothesis-building, not proof of human outcomes.

D · Extrapolated / Real-World Protocol Convention

Common research-community or clinic-style protocol logic where direct published evidence is thin. These entries require the strongest warnings and the least confident wording.

02 / METHODOLOGY

How We Build Dosing Protocols

1
Gather From Multiple Sources
For each compound, we pull dosing data from at least 8 independent sources: FDA prescribing information, published clinical trials, compounding pharmacy protocols, peer-reviewed research papers, provider SOPs, and respected dosing references. No single source dictates our numbers.
2
Cross-Reference For Consistency
We compare recommendations across sources to identify consensus ranges. When sources agree, we have high confidence. When they disagree, we dig deeper to understand why — and present the most clinically validated range.
3
Average & Document
We calculate the averaged low/mid/high dose ranges from all cross-referenced sources. Every entry in our catalog includes citation notes so you can verify the research yourself.
4
Weekly Audits
The research doesn't stop. Every week we re-check the latest published studies, FDA updates, and safety notices. When something changes, our catalog updates. You always get the most current data available.
03 / WHERE OUR DATA COMES FROM

Primary Source Categories

🏛️ FDA-Approved Drug Labels

When a compound has an FDA-approved form, that prescribing information is our gold standard.

📚 Peer-Reviewed Clinical Trials

Published research from medical journals — the foundation of evidence-based dosing.

⚗️ Compounding Pharmacy Protocols

Licensed 503B and 503A compounding pharmacies that produce research peptides provide clinical dosing guidance.

🔬 Research Databases & Dosing References

Specialized peptide research databases used by clinicians and researchers.

🏥 Clinical SOPs & Provider Protocols

Standard Operating Procedures from licensed wellness clinics and longevity practices.

📖 Peer-Reviewed Databases

Primary research sources where new studies are published.

04 / AUDIT SCHEDULE

Continuous Research Verification

Our data isn't static. We run a continuous audit process to make sure every dose and protocol reflects the latest evidence.

AUDIT
New peer-reviewed publications review
AUDIT
FDA notices & safety updates
MONTHLY
Full catalog dose verification
QUARTERLY
Methodology review & source expansion
ONGOING
User feedback & field-reported issues
ONGOING
New compound research for catalog expansion
05 / IMPORTANT DISCLAIMER

What This Tool Is (And Isn't)

What we are: An education and research consolidation tool. We collect published data from multiple clinical and pharmaceutical sources and present it in one place so you can research peptides and hormone protocols with transparent sourcing.
What we are not: Medical advice. Apex Protocol LLC is not a licensed medical provider. We do not diagnose, treat, or prescribe. No information on this platform constitutes medical advice, clinical interpretation, or treatment recommendation.

All peptide compounds referenced may be research chemicals not approved by the FDA for human use (except where FDA approval is explicitly noted — e.g., Scenesse® for EPP, Wegovy® for weight management, etc.).

Information is provided solely for educational purposes based on publicly available scientific literature. Individual risks and appropriate use cannot be determined without evaluation by a licensed healthcare provider. Do not begin, modify, or stop any health protocol without consulting a qualified medical professional.

Always verify our information against your own research and your healthcare provider's guidance. We're confident in our methodology, but you should never take any single source — including ours — as absolute truth.

06 / FOUND AN ERROR?

Help Us Stay Accurate

If you find a dose, protocol, or citation that looks wrong, tell us. Every correction makes the tool more reliable for the next person.

Email: research@apexdosing.com

Please include: the peptide, the specific number/claim you're disputing, your source, and (ideally) the primary research we should be citing instead. We respond to every research correction within 48 hours.